Your browser doesn't support javascript.
loading
Clinical Characteristics and Outcomes of Disseminated Strongyloidiasis in the United States-A Multicenter Network Analysis.
Henao-Martínez, Andrés F; Olivo Freites, Christian; Agudelo Higuita, Nelson I; Marcos, Luis A; Chastain, Daniel B; Mohareb, Amir M; Tuells, Jose; Villalpando-Carrion, Salvador; Franco-Paredes, Carlos.
Afiliación
  • Henao-Martínez AF; Division of Infectious Diseases, Department of Medicine, University of Colorado Denver, Aurora, Colorado.
  • Olivo Freites C; Ryan Health, Infectious Diseases, New York, New York.
  • Agudelo Higuita NI; University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
  • Marcos LA; Instituto de Enfermedades Infecciosas y de Parasitología Antonio Vidal, Tegucigalpa, Honduras.
  • Chastain DB; Division of Infectious Diseases, Departments of Medicine, Microbiology and Immunology, Stony Brook University, Stony Brook, New York.
  • Mohareb AM; Department of Clinical and Administrative Pharmacy, University of Georgia College of Pharmacy, Albany, Georgia.
  • Tuells J; Center for Global Health, Massachusetts General Hospital, Boston, Massachusetts.
  • Villalpando-Carrion S; Division of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts.
  • Franco-Paredes C; Department of Medicine, Harvard Medical School, Boston, Massachusetts.
Am J Trop Med Hyg ; 111(1): 89-92, 2024 Jul 03.
Article en En | MEDLINE | ID: mdl-38806043
ABSTRACT
Human strongyloidiasis is a potentially life-threatening parasitic disease among immunocompromised hosts. We aim to determine the factors and mortality associated with disseminated strongyloidiasis. We conducted a U.S.-based multicenter retrospective cohort study to determine 90-day clinical outcomes for people diagnosed with Strongyloides infection in the TriNetX patient database. We identified adult patients with the International Classification of Diseases (10th revision, clinical modification) code for Strongyloides infection (B78) or a positive Strongyloides IgG antibody test and captured outcomes at 90 days. We identified 5,434 patients with strongyloidiasis, of whom 48 had disseminated strongyloidiasis for 0.9% prevalence of disseminated disease. Systemic connective tissue disorders, pulmonary eosinophilia, liver cirrhosis, blood disorders (monoclonal gammopathy, aplastic anemia, and lymphoid malignancy), malnutrition, alcohol use disorder, and transplantation status were frequent in patients with disseminated disease. Mortality was significantly higher in people with disseminated disease at 30 days (21%). The 90-day risk of hospitalization, bacteremia, and acute respiratory distress syndrome (ARDS) was higher in those with disseminated infection. People with disseminated strongyloidiasis had a heightened risk of hospitalization, bacteremia, acute respiratory distress syndrome, and mortality. The population at risk for severe strongyloidiasis infection is evolving, reflecting conditions in which glucocorticoids or additional immunosuppressive medications are commonly used for treatment.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estrongiloidiasis Límite: Adult / Aged / Animals / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Am J Trop Med Hyg Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Estrongiloidiasis Límite: Adult / Aged / Animals / Female / Humans / Male / Middle aged País/Región como asunto: America do norte Idioma: En Revista: Am J Trop Med Hyg Año: 2024 Tipo del documento: Article Pais de publicación: Estados Unidos